循环肿瘤DNA评估预测局部晚期食管鳞癌术后复发风险
这项前瞻性观察研究纳入28例接受新辅助化疗后手术的局部晚期食管鳞癌患者,用个体化肿瘤信息16-plex mPCR-NGS法在多时间点检测ctDNA。结果显示术后MRD窗口ctDNA阳性者复发率100%、阴性者30.4%,RFS显著更差(HR 30.99,P<0.0001)。
要点
- 新辅助化疗后术前ctDNA阳性者复发率77.8%,阴性者27.8%,RFS更差(HR 4.56,P=0.01)。
- 术后2-16周MRD窗口ctDNA阳性者复发率100%,阴性者30.4%,RFS显著更差(HR 30.99,P<0.0001)。
- 术后>16周随访期可检出ctDNA与不良RFS显著相关(HR 27.34,P=0.003)。
核心结论
- 基于ctDNA的MRD评估可能对评价食管鳞癌患者有价值,尤其在新辅助化疗后和术后场景。
研究设计与样本
- 前瞻性纳入计划接受新辅助化疗后手术的局部晚期食管鳞癌患者。
- 本报告回顾性分析28例接受根治性手术且肿瘤组织全外显子测序成功的患者。
- 采用个体化肿瘤信息16-plex mPCR-NGS法在新辅助化疗前、新辅助化疗后术前、术后及随访纵向多时间点检测ctDNA。
主要发现
- 新辅助化疗前ctDNA检出率:I期50%,II、III、IV期100%。
- 新辅助化疗后术前ctDNA检出率33.3%。
- ctDNA阳性者复发率77.8%,阴性者27.8%,RFS显著更差(HR 4.56,P=0.01)。
- 术后MRD窗口(2-16周)ctDNA阳性者复发率100%,阴性者30.4%,RFS显著更差(HR 30.99,P<0.0001)。
- 术后随访期(>16周)可检出ctDNA与不良RFS显著相关(HR 27.34,P=0.003)。
临床怎么用
- 可考虑在新辅助化疗后术前及术后MRD窗口检测ctDNA,辅助识别食管鳞癌高复发风险患者。
局限性
- 本报告仅纳入28例接受根治性手术且全外显子测序成功的患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between perioperative ctDNA status and prognosis in patients with esophageal squamous cell carcinoma (ESCC). BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for assessing molecular residual disease (MRD) in various malignancies. However, there are limited studies evaluating the utility of ctDNA for predicting recurrence risk in patients with ESCC. METHODS: We prospectively enrolled patients with locally advanced ESCC who were scheduled to receive neoadjuvant chemotherapy (NAC) followed by surgery. This report retrospectively analyzed ctDNA with a personalized, tumor-informed 16-plex mPCR-NGS assay at multiple time points: pre-NAC, post-NAC but before surgery, postoperatively, and longitudinally during follow-up. RESULTS: A total of 28 patients who underwent curative surgery and had successful whole-exome sequencing analyses of tumor tissue samples were included in this report. At the pre-NAC time point, ctDNA was detected in 50% of patients with stage I and 100% of those with stages II, III, and IV. Post-NAC but before surgery, ctDNA was detected in 33.3% of patients. The recurrence rate was 77.8% in ctDNA-positive patients compared to 27.8% in ctDNA-negative patients, with significantly worse recurrence-free survival (RFS) for ctDNA-positive patients vs. ctDNA-negative patients (HR: 4.56, P =0.01). In patients analyzed during the MRD window (2-16 weeks post-surgery), the recurrence rate was 100% in ctDNA-positive patients compared with 30.4% in ctDNA-negative patients, with significantly worse RFS (HR: 30.99, P <0.0001). Similarly, during surveillance (>16 weeks postsurgery), detectable ctDNA was significantly associated with poor RFS (HR: 27.34, P =0.003). CONCLUSIONS: This study suggests that ctDNA-based MRD assessment may be valuable for evaluating patients with ESCC, particularly in post-NAC and postsurgical settings.
引用
- Takei S, Kotani D, Laliotis G, et al. Circulating Tumor DNA Assessment to Predict Risk of Recurrence After Surgery in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study. Ann Surg. 2025. PMID: 40115982. doi:10.1097/SLA.0000000000006699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。